公开(公告)号：US20230051701A1

公开(公告)日：2023-02-16

申请号：US17737403

申请日：2022-05-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nils Lonberg ,  Alan J. Korman ,  Bryan C. Barnhart ,  Aaron P. Yamniuk ,  Mohan Srinivasan ,  Karla A. Henning ,  Ming Lei ,  Emanuela Sega ,  Angela Goodenough ,  Maria N. Jure-Kunkel ,  Guodong Chen ,  John S. Sack ,  Richard Huang ,  Martin J. Corbett ,  Joseph E. Myers, JR. ,  Liang Schweizer ,  Sandra V. Hatcher ,  Haichun Huang ,  Pingping Zhang

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  G01N33/573 ,  A61K47/68 ,  A61K45/06 ,  G01N33/574

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

公开(公告)号：US10690674B2

公开(公告)日：2020-06-23

申请号：US15578874

申请日：2016-06-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xi-Tao Wang ,  Olufemi A. Adelakun ,  Anne C. Lewin ,  Alan J. Korman ,  Mark J. Selby ,  Changyu Wang ,  Haichun Huang ,  Karla A. Henning ,  Nils Lonberg ,  Mohan Srinivasan ,  Michelle Minhua Han ,  Guodong Chen ,  Richard Y. Huang ,  Indrani Chakraborty ,  Susan Chien-Szu Wong ,  Huiming Li

IPC: G01N33/566 ,  G01N33/574 ,  C07K16/28

Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.